Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin

Show simple item record Ylösmäki, Erkko Fusciello, Manlio Martins, Beatriz Feola, Sara Hamdan, Firas Chiaro, Jacopo Ylösmäki, Leena Vaughan, Matthew J. Viitala, Tapani Kulkarni, Prasad S. Cerullo, Vincenzo 2021-09-20T11:03:01Z 2021-09-20T11:03:01Z 2021
dc.identifier.citation Ylösmäki , E , Fusciello , M , Martins , B , Feola , S , Hamdan , F , Chiaro , J , Ylösmäki , L , Vaughan , M J , Viitala , T , Kulkarni , P S & Cerullo , V 2021 , ' Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin ' , Journal for Immunotherapy of Cancer , vol. 9 , no. 7 , 002707 .
dc.identifier.other PURE: 168612987
dc.identifier.other PURE UUID: 3de12499-009d-40ad-b4ab-128276fd7f7c
dc.identifier.other WOS: 000691848000002
dc.identifier.other ORCID: /0000-0001-9074-9450/work/100257731
dc.description.abstract Background Intratumoral BCG therapy, one of the earliest immunotherapies, can lead to infiltration of immune cells into a treated tumor. However, an increase in the number of BCG-induced tumor-specific T cells in the tumor microenvironment could lead to enhanced therapeutic effects. Methods Here, we have developed a novel cancer vaccine platform based on BCG that can broaden BCG-induced immune responses to include tumor antigens. By physically attaching tumor-specific peptides onto the mycobacterial outer membrane, we were able to induce strong systemic and intratumoral T cell-specific immune responses toward the attached tumor antigens. These therapeutic peptides can be efficiently attached to the mycobacterial outer membrane using a poly-lysine sequence N-terminally fused to the tumor-specific peptides. Results Using two mouse models of melanoma and a mouse model of colorectal cancer, we observed that the antitumor immune responses of BCG could be improved by coating the BCG with tumor-specific peptides. In addition, by combining this novel cancer vaccine platform with anti-programmed death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy, the number of responders to anti-PD-1 immunotherapy was markedly increased. Conclusions This study shows that intratumoral BCG immunotherapy can be improved by coating the bacteria with modified tumor-specific peptides. In addition, this improved BCG immunotherapy can be combined with ICI therapy to obtain enhanced tumor growth control. These results warrant clinical testing of this novel cancer vaccine platform. en
dc.format.extent 13
dc.language.iso eng
dc.relation.ispartof Journal for Immunotherapy of Cancer
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject adaptive immunity
dc.subject immunity
dc.subject cellular
dc.subject immunogenicity
dc.subject vaccine
dc.subject immunotherapy
dc.subject active
dc.subject B16 MELANOMA
dc.subject TUMOR-GROWTH
dc.subject VIRUS
dc.subject 3122 Cancers
dc.subject 317 Pharmacy
dc.title Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin en
dc.type Article
dc.contributor.organization ImmunoViroTherapy Lab
dc.contributor.organization Division of Pharmaceutical Biosciences
dc.contributor.organization Drug Research Program
dc.contributor.organization TRIMM - Translational Immunology Research Program
dc.contributor.organization Division of Pharmaceutical Chemistry and Technology
dc.contributor.organization Pharmaceutical biophysics group
dc.contributor.organization Digital Precision Cancer Medicine (iCAN)
dc.description.reviewstatus Peer reviewed
dc.relation.issn 2051-1426
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
e002707.full.pdf 1.451Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record